v3.25.3
Non-Current Provisions And Other Non-Current Liabilities - Summary of Non-Current Provisions and Other Non-Current Liabilities (Details) - EUR (€)
€ in Millions
Jun. 30, 2025
Dec. 31, 2024
Disclosure Of Non-current Provisions [Line Items]    
Provisions € 5,003 € 5,762
Other non-current liabilities [1] 2,113 2,334
Non-current provisions [2] 7,116 € 8,096
Antibodies Collaboration Agreement | Swedish Orphan Biovitrum AB    
Disclosure Of Non-current Provisions [Line Items]    
Other non-current liabilities 1,756  
Antibodies Collaboration Agreement | Swedish Orphan Biovitrum AB | Later than one year and not later than five years [member]    
Disclosure Of Non-current Provisions [Line Items]    
Other non-current liabilities 1,027  
Antibodies Collaboration Agreement | Swedish Orphan Biovitrum AB | Total    
Disclosure Of Non-current Provisions [Line Items]    
Other non-current liabilities € 2,293  
[1] Includes €1,756 million at June 30, 2025 relating to the liability for royalties payable to Sobi on net sales of Beyfortus in the United States ( see Note C.2. to the consolidated financial statements for the year ended December 31, 2024) . Given the method used to calculate royalties payable, an increase or decrease in sales forecasts would lead to a proportionate change in the amount of the liability. The nominal value of payments estimated to be due within more than one year but less than five years is €1,027 million; the nominal value of payments estimated to be due after more than five years is €2,293 million.
[2] These unaudited condensed half year consolidated financial statements as of June 30, 2025 should be read in conjunction with Sanofi’s audited consolidated financial statements as of December 31, 2024.